# US 2026/0097056 A1 · Syk activators and inhibitors in neurodegenerative diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097056 A1
- Document ID: US20260097056A1
- Status: Published application
- Kind: A1
- Application number: 19/112,913
- Filed: 2023-09-20
- Published: 2026-04-09
- Earliest claimed: 2022-09-20
- Assignees: University of Virginia Patent Foundation
- Applicants: University of Virginia Patent Foundation
- Inventors: John R. Lukens; Hannah Elzabeth Ennerfelt; Elizabeth Frost
- Web page: https://patentgrep.com/patent/US20260097056A1

## CPC

- A61K 31/702: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/4995: Pyrazines or piperazines forming part of bridged ring systems
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5383: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/716: Glucans
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods to treat neurodegenerative disease.

## Claims

### Claim 1

A method to treat or prevent Aβ-driven neurodegeneration or a demyelinating disease comprising administering an activator of SYK to a subject in need thereof.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

A method to generate an increase in spatial learning and/or memory in Aβ-driven neurodegeneration or a demyelinating disease comprising administering an activator of SYK to a subject in need thereof.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 9 (depends on 8)

The method of claim 8, wherein the mammal is a human.

### Claim 10 (depends on 1)

The method of claim 1, wherein the SYK activator comprises a β-D-glucan.

### Claim 11 (depends on 1)

The method of claim 1, wherein the SYK activator comprises a ligand for CLEC7A.

### Claim 12 (depends on 1)

The method of claim 1, wherein the SYK activator comprises pustulan.

### Claim 13 (depends on 1)

The method of claim 1, wherein the Aβ-driven neurodegeneration is Alzheimer's Disease (AD).

### Claim 14 (depends on 1)

The method of claim 1, wherein the demyelinating disease is multiple sclerosis (MS) Balo's disease, acute-disseminated encephalomyelitis, progressive multifocal leukoencephalopathy, Charcot-Marie-Tooth Disease, Guillain-Barre Syndrome (GBS), HTLV-I Associated Myelopathy (HAM), Neuromyelitis Optica (Devic's Disease), Schilder's Disease, Transverse Myelitis or extrapontine myelinolysis.

### Claim 15

A method to treat or prevent a tauopathy comprising administering an inhibitor of SYK to a subject in need thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein the subject is a mammal.

### Claim 17 (depends on 16)

The method of claim 16, wherein the mammal is a human.

### Claim 18 (depends on 15)

The method of claim 15, wherein the SYK inhibitor comprises GSK 143, Gusacitinib, R406, Fostamatinib, Piceatannol, Dehydroabietic acid, Cerdulatinib, MNS (3,4-Methylenedioxy-β-nitrostyrene), R112, BAY-61-3606, RO9021, Entospletinib, PRT-060318 2HCl, PRT062607 (P505-15) HCl, TAK-659, SRX3207, Lanraplenib or salts, compositions and combinations thereof.

### Claim 19 (depends on 15)

The method of claim 15, wherein the tauopathy comprises Pick disease, progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease, frontotemporal lobar degeneration (FTLD-Tau), Alzheimer disease (AD; a secondary tauopathy), chronic traumatic encephalopathy, post-encephalitic parkinsonism or Parkinsonism linked to chromosome 17.
